X
[{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Randomized In TRS4VISION Phase-III Clinical Trial In Patients With Active Non-Infectious Anterior Uveitis Including Patients With Uveitic Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Tarsier Pharma"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidate","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Orasis Pharmaceuticals"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orasis Pharmaceuticals Announces Phase 2b Trial Efficacy and Safety Results of Novel Presbyopia Eye Drop Candidate, CSF-1, at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Orasis Pharmaceuticals"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma Announces Participation in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Tarsier Pharma"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Orasis Pharmaceuticals' New Drug Application for CSF-1 for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Orasis Pharmaceuticals"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HanAll Biopharma Announces Results from Phase III Randomized, Double-Masked Active Treatment-Controlled VELOS-3 Trial Evaluating Tanfanercept 0.25% for Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Hanall Biopharma"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma Announces Results from a Phase 3 Clinical Trial in Subjects with Noninfectious Anterior Uveitis Including Subjects with Uveitic Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Tarsier Pharma"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma Announces Successful Type C Meeting with FDA for TRS01 in Noninfectious Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Tarsier Pharma"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma Receives FDA Agreement Under Special Protocol Assessment (SPA) for Tarsier-04 Phase 3 Trial of TRS01 Ophthalmic Solution for the Treatment of Non-infectious Uveitis including Uveitic Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Tarsier Pharma"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
TRS01 (dazdotuftide) is a first-in-class NF-κB signaling pathway inhibitor, which is under phase 3 clinical development for the treatment of non-infectious uveitis including uveitic glaucoma.
Lead Product(s):
TRS01
Therapeutic Area: Ophthalmology
Product Name: TRS01
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 16, 2024
Details:
TRS01 (dazdotuftide) is a bio-inspired novel proprietary technology platform, based on a New Chemical Entity (NCE) with a disruptive mechanism of action that modulate macrophages from inflammatory macrophages (M1) to IL-10 secreting ant-inflammatory macrophages (M2).
Lead Product(s):
TRS01
Therapeutic Area: Ophthalmology
Product Name: TRS01
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 13, 2023
Details:
TRS01 (dazdotuftide) is a bio-inspired novel proprietary technology platform, based on a New Chemical Entity (NCE) with a disruptive mechanism of action that modulate macrophages from inflammatory macrophages (M1) to IL-10 secreting ant-inflammatory macrophages (M2).
Lead Product(s):
TRS01
Therapeutic Area: Ophthalmology
Product Name: TRS01
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 23, 2023
Details:
HL036 (tanfanercept) is a novel, potentially first-in-class topical anti-inflammatory treatment targeting tumor necrosis factor alpha for the treatment of dry eye disease, co-developed with Daewoong Pharmaceutical.
Lead Product(s):
Tanfanercept
Therapeutic Area: Ophthalmology
Product Name: HL036
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Daewoong Pharmaceutical
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 19, 2023
Details:
CSF-1 is a preservative-free formulation of low-dose pilocarpine, a muscarinic cholinergic agonist used on the eye to treat elevated intraocular pressure, various types of glaucoma, and to induce miosis. It is being investigated for the treatment of presbyopia.
Lead Product(s):
Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology
Product Name: CSF-1
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 21, 2023
Details:
TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma – that is considered an end-stage condition of uveitis.
Lead Product(s):
TRS01
Therapeutic Area: Ophthalmology
Product Name: TRS01
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 08, 2022
Details:
Two presentations on Phase 2b clinical trial show CSF-1 met primary endpoints and achieved statistically significant and clinically meaningful improvements in distance-corrected near visual acuity (DCNVA) for participants with presbyopia.
Lead Product(s):
Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology
Product Name: CSF-1
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 23, 2022
Details:
By repurposing existing and well-studied molecules, CSF-1 is designed to be effective, safe, comfortable, and easy-to-use, corrective eye drop for the treatment of presbyopia as an alternative to reading glasses.
Lead Product(s):
CSF-1
Therapeutic Area: Ophthalmology
Product Name: CSF-1
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 15, 2022
Details:
TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma.
Lead Product(s):
TRS01
Therapeutic Area: Ophthalmology
Product Name: TRS01
Highest Development Status: Phase III
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 22, 2021